Tailor, Imran K.
Alshehry, Nawal F.
Zaidi, Syed Z.
Marei, Mohammed A.
Motabi, Ibrahim H.
Alfayez, Mansour
Altaf, Syed Y.
2020-09-22T17:19:19Z
2020-09-22T17:19:19Z
2020
1658-3876
https://doi.org/10.1016/j.hemonc.2020.08.002
http://hdl.handle.net/20.500.12010/13586
Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedly have poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of ≥10% [1], [2], [3]. A recent small study reported a high mortality rate among patients with myeloma and concurrent COVID-19 infection [4]. Interestingly, one large study reported that active or recent chemotherapy was not a predictor of severe disease, whereas checkpoint inhibitor therapy and age over 65 years were associated with adverse outcomes [1]. Here we describe the outcomes of three consecutive patients with myeloma and concurrent COVID-19 infection admitted at our tertiary care centre between April and June 2020, whilst on lenalidomide-based therapy, two of whom underwent autologous stem cell transplant, with at least 30 days of follow-up.
3 páginas
application/pdf
eng
Hemonic
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
COVID5 19
Myeloma patients
Lenalidomide-based therapy
Outcome of myeloma patients with COVID5 19 on active lenalidomide-based therapy: 6 Does lenalidomide protect from severe 7 COVID-19?
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/acceptedVersion
Abierto (Texto Completo)
https://doi.org/10.1016/j.hemonc.2020.08.002
http://purl.org/coar/resource_type/c_2df8fbb1